U.S. markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
257.01-0.82 (-0.32%)
At close: 04:00PM EDT
258.00 +0.99 (+0.39%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close257.83
Bid256.99 x 800
Ask256.60 x 900
Day's Range255.25 - 259.23
52 Week Range250.31 - 319.76
Avg. Volume1,004,384
Market Cap37.221B
Beta (5Y Monthly)0.13
PE Ratio (TTM)14.04
EPS (TTM)18.31
Earnings DateOct 23, 2023 - Oct 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est333.66
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biogen Inc.
    Two-Thirds Through a Positive Investing YearThe Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Catalent Inc. (CTLT); Splunk Inc (SPLK); Twilio Inc (TWLO); CIENA Corp. (CIEN) and the Focus List deletions are Biogen Inc (BIIB); Arista Networks Inc (ANET); Netflix Inc (NFLX); Shopify Inc (SHOP).
    Fair Value
    Economic Moat
    17 days agoArgus Research
View more
  • GlobeNewswire

    FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

    TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

  • Investor's Business Daily

    Is Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?

    Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer’s drugs. But is LLY stock a buy now? Here's what you should know.

  • Motley Fool

    Is Biogen Stock a Buy Now?

    It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.